Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Daniel L. Suzman"'
Publikováno v:
Cancers, Vol 7, Iss 4, Pp 1983-1993 (2015)
Activity in the Hedgehog pathway, which regulates GLI-mediated transcription, is important in organogenesis and stem cell regulation in self-renewing organs, but is pathologically elevated in many human malignancies. Mutations leading to constitutive
Externí odkaz:
https://doaj.org/article/019cab95fdfb41b297b7b2cdd9328b8c
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 6 (2014)
Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have seen an abundance of new agents approved by the United States Food and Drug Administration in the last decade for a disease that was previously difficult to treat
Externí odkaz:
https://doaj.org/article/fbe9364e270240039aa81618437fe931
Autor:
Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Amna Ibrahim, Rajeshwari Sridhara, Lijun Zhang, Joyce Cheng, Daniel L. Suzman, Dow-Chung Chi, Jamie R. Brewer, Chana Weinstock, Michael Brave
Supplementary Tables S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005fa37d228ce4a21d5b624079b9f4c1
https://doi.org/10.1158/1078-0432.22474730.v1
https://doi.org/10.1158/1078-0432.22474730.v1
Autor:
Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Amna Ibrahim, Rajeshwari Sridhara, Lijun Zhang, Joyce Cheng, Daniel L. Suzman, Dow-Chung Chi, Jamie R. Brewer, Chana Weinstock, Michael Brave
The FDA has approved three androgen receptor inhibitors—enzalutamide, apalutamide, and darolutamide—for the treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). These approvals were all based on randomized, doub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::732ae92e2162726573271f66b2078649
https://doi.org/10.1158/1078-0432.c.6528890
https://doi.org/10.1158/1078-0432.c.6528890
Autor:
Tatiana M. Prowell, Chana Weinstock, Jason A. Efstathiou, Seth P. Lerner, Daniel L. Suzman, Vinay Duddalwar, Hui Zhang, Donna E. Hansel, Andrea B. Apolo, Evan Y. Yu, Richard Pazdur, Matthew D. Galsky, Elaine Chang, Julia A. Beaver, Paul G. Kluetz, Elizabeth R. Plimack, Harpreet Singh, Kirsten B. Goldberg, Rick Bangs, Ashish M. Kamat, Stephanie Chisolm
Publikováno v:
Nature Reviews Urology. 19:37-46
The success of the use of novel therapies in the treatment of advanced urothelial carcinoma has contributed to growing interest in evaluating these therapies at earlier stages of the disease. However, trials evaluating these therapies in the neoadjuv
Autor:
Sundeep Agrawal, Anup K. Amatya, Harpreet Singh, Lijun Zhang, Mehrnoosh Hadadi, Vishal Bhatnagar, Amna Ibrahim, Paul G. Kluetz, Bellinda L. King-Kallimanis, Julia A. Beaver, Shenghui Tang, Yutao Gong, Michael Brave, Mitchell S. Anscher, Chana Weinstock, Jaleh Fallah, Elaine Chang, Laleh Amiri-Kordestani, Richard Pazdur, James X Xu, Dow-Chung Chi, Daniel L. Suzman, Jamie R. Brewer, Marc R. Theoret, Kirsten B. Goldberg
Publikováno v:
The Lancet Oncology. 22:1230-1239
Little is known about the benefit-risk profile of second-generation androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. We aimed to examine the efficacy and safety of second-generation androgen receptor
Autor:
Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy John, Wei Chen, Tiffany K. Ricks, Gang Niu, Anthony Fotenos, Min Wang, Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Amna Ibrahim, Paul G. Kluetz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate ca
Autor:
Mirat Shah, Daniel L. Suzman, Mallorie H. Fiero, Danielle Krol, Amna Ibrahim, Laleh Amiri-Kordestani, Soma Ghosh, Christina Brus, Gwynn Ison, Tatiana M. Prowell, Shenghui Tang, Reena Philip, Sakar Wahby, Melanie Royce, Shaily Arora, Tara Berman, Julia A. Beaver, Jennifer J Gao, Preeti Narayan, Richard Pazdur, Suparna Wedam, Erik Bloomquist, Christy L. Osgood
Publikováno v:
Clin Cancer Res
Over the last decade, there has been tremendous progress in the treatment of patients with gynecologic cancers with a changing therapy landscape. This summary provides an overview of U.S. Food and Drug Administration (FDA) approvals for gynecologic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd0d59d29d17c905da03926e5cca53d
https://europepmc.org/articles/PMC8923904/
https://europepmc.org/articles/PMC8923904/
Autor:
Amna Ibrahim, Chana Weinstock, Sundeep Agrawal, Kirsten B. Goldberg, Julia A. Beaver, Shenghui Tang, Elaine Chang, Daniel L. Suzman, Jamie Renee Brewer, Richard Pazdur, Rajeshwari Sridhara, Harpreet Singh, Laura L. Fernandes, James Xu, Lijun Zhang, Joyce Cheng, Erik Bloomquist, Marc R. Theoret, Diqiong (Joan) Xie
Publikováno v:
Clinical Cancer Research. 26:6406-6411
The development and review of combination drug regimens in oncology may present unique challenges to investigators and regulators. For regulatory approval of combination regimens, it is necessary to demonstrate the contribution of effect of each mono
Autor:
Jaleh Fallah, Chana Weinstock, Gautam U. Mehta, Michael H. Brave, William F. Pierce, Richard Pazdur, Abhilasha Nair, Daniel L. Suzman, Laleh Amiri-Kordestani
Publikováno v:
Clinical Cancer Research. 29:685-685